C5 and infection: However, during severe infections that are followed by strong complement activation, which produces high C3b densities, the commonly observed low levels of residual TP activity in PNH patients exacerbate and thus causes pharmacodynamic breakthrough hemolysis in Eculizumab (or potentially other anti-C5) treated PNH patient.